VRTX

Nasdaq

VERTEX PHARMACEUTICALS INC / MA

Health Care, Biotechnology

$496.07

close 7 Aug 2026

+32.48%

52-week change

$125.68B

market cap

$362.50

$533.67

52-week range

Expected price

$433.31 – $529.60

Current price

$496.07

Signal

Appears fairly valued

A historical-multiple reference, never a fair-value claim. The band uses only data public at each date and ends at the latest month — no forward estimates.

Current multiples

P/E (TTM)28.89x

P/S (TTM)9.98x

P/B6.21x

EV/EBITDA (TTM)—

FCF yield (TTM)3.02%

PEG (TTM, GAAP)4.72

Context

P/E, own 5-year average27.80x

P/E, sector median29.65x*

Price at 5-year median P/E$475.36*

Forward — analyst consensus

Forward P/E (FY2026)26.28x*

Forward P/E (FY2027)22.94x

Forward PEG1.81*

Consensus EPS FY2026 (15 analysts)$18.88

EPS growth (FY2026→FY2027)14.55%

Revenue growth (FY2026)9.86%

Street view

Price target (mean)$559.28*

Target upside12.74%

Ratings (buy / hold / sell)23 / 5 / 1

FY2026 EPS revisions, 30d (up / down)4 / 4

5-year history

Dashed line: average of month-end values

P/E (TTM)

P/S (TTM)

P/B

FCF yield (TTM)

period to 30 Jun 2026, filed 4 Aug 2026, close 7 Aug 2026

Discounted cash flow

Ten projected years plus a perpetuity, prefilled from filings — a model to argue with, never a fair-value claim.

Free cash flow, last ten years and TTM

5Y CAGR +1.30%

Assumptions

Growth rate, years 1–10%

Perpetual growth%Discount rate%

Base FCF$M

As filed — not assumptions

Current price$496.07

Cash & equivalents$6.14B

Total debt—

Shares outstanding253.35M

Result

DCF price per share—

Current price$496.07

Margin of safety—

PV of years 1–10$27.14B

PV of terminal value$37.29B

Equity value—

Market-implied growth—

Projected FCF, years 1–10

Hover for PV and growth

Projection detail

Override growth for any year; blank years use the uniform rate

Year	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	Terminal
Growth, %											2.5
FCF	$3.85B	$3.90B	$3.95B	$4.00B	$4.05B	$4.10B	$4.16B	$4.21B	$4.26B	$4.32B	$80.50B
PV	$3.56B	$3.34B	$3.13B	$2.94B	$2.76B	$2.58B	$2.42B	$2.27B	$2.13B	$2.00B	$37.29B

period to 30 Jun 2026, filed 4 Aug 2026, close 7 Aug 2026